Zambeletti's responsibility will lie in strategic development and he will also chair the nomination committee.
During a 19 year career as an investment banker, Tiziana said, Zambeletti led the European healthcare investment banking team at JPMorgan for eight years before taking up the same position at Credit Suisse for a further five years.
Since 2013 he has been an independent strategic advisor to life science companies on merger and acquisitions, out-licensing deals, and financing strategy. He is a non-executive director of Qardio Inc, Summit Therapeutics PLC, Nogra Pharma Ltd, Faron Pharmaceuticals OY, and DS Biopharma Ltd.
Gabriele Cerrone, chairman & founder said: "The company is now at a stage where we are moving into the clinic and hoping to rapidly advance several programs; we have achieved this with a very small permanent staff and as we advance operationally we will need to create a clear order of priorities, make additional hires and refine our operational strategy".
He added: "Leopoldo has agreed to join us to help with the next stage of our development and I believe that his track-record and affiliations speak for themselves, not least his directorship with Advanced Accelerator Application SA, which was recently sold to Novartis for
"In my opinion we could not have found an individual better placed to refine and direct strategic development for the Company and I am delighted that he has agreed to join us on our journey into the next, fundamental and critical stage of the life of the company".
Shares in Tiziana were trading up 1.7% at
Faron Pharma (FARN)